What Emerging Research Says About PRP and Your Spine
Compass Pain and Wellness | Cottonwood Heights, Utah
Chronic low back pain (LBP) is rarely just a symptom. For millions of people, it is a persistent, life-altering condition. As one of the leading causes of disability for adults between the ages of 45 and 65, LBP represents one of the most costly musculoskeletal challenges in the United States.
For those whose pain has not responded to physical therapy and medication, the clinical path often narrows to a difficult choice: continue living with restricted mobility or undergo a major, invasive spinal fusion.
This dilemma exists in part because of a fundamental biological limitation. The adult intervertebral disc (IVD) is the largest avascular structure in the human body. Without a direct blood supply, the disc relies on passive diffusion for nutrients, making recovery from damage extremely difficult. Once degeneration begins—marked by dehydration of the nucleus pulposus and the development of painful tears in the annulus fibrosus—the disc has very limited intrinsic capacity for self-repair.
Against this backdrop, a growing body of early-stage research is exploring whether regenerative approaches may offer a complementary path—one that aims to support the body’s own repair processes rather than surgically removing or fusing damaged segments. Platelet-Rich Plasma (PRP) is one of the most actively studied of these approaches.
What Is Platelet-Rich Plasma (PRP)?
PRP is an autologous preparation—meaning it is derived from a patient’s own blood—that concentrates platelets at levels above their normal physiological baseline.
Each platelet contains approximately 50 to 80 alpha-granules, which store over 300 soluble proteins. When activated, these granules release a range of bioactive growth factors, including:
- Transforming Growth Factor-β1 (TGF-β1)
- Platelet-Derived Growth Factor (PDGF)
- Vascular Endothelial Growth Factor (VEGF)
These proteins play multiple roles in the body’s natural wound-healing cascade.
Emerging molecular research is also examining additional mechanisms, such as the role of exosomal miR-141-3p in activating the Keap1-Nrf2 pathway—a cellular defense system involved in managing oxidative stress and inflammation.
In preclinical and early clinical research, PRP has been investigated for three potential restorative effects on degenerating discs:
- Supporting structural synthesis: Encouraging the production of collagen and proteoglycans that form the disc’s internal matrix.
- Modulating inflammatory activity: Reducing the expression of enzymes like MMP-3 and COX-2 that are associated with tissue breakdown.
- Promoting disc hydration: Supporting the proliferation of nucleus pulposus cells, which help maintain the hydrostatic pressure needed for load-bearing.
A systematic review of the literature summarized the hypothesis: in earlier stages of disc degeneration, the remaining functional cells within the disc may respond to concentrated growth factors with increased proliferation and extracellular matrix accumulation, which could help preserve structure and function.
This remains an active area of investigation, and larger, long-term clinical trials are needed to confirm these effects in broader patient populations.
How Does PRP Compare to Corticosteroid Injections?
For decades, the standard interventional response to spinal pain has been the corticosteroid injection. Steroids provide rapid relief by suppressing inflammation, but their effects are often temporary, and some research suggests that repeated use may have negative long-term effects on spinal tissues.
PRP works through a different mechanism. Rather than chemically suppressing inflammation, it aims to deliver concentrated growth factors to support the body’s natural repair processes.
In a randomized controlled study by Ruiz-Lopez et al., researchers compared Leukocyte-rich PRP (Lr-PRP) to corticosteroids in patients receiving caudal epidural injections for chronic degenerative spinal pain. While both groups saw initial improvement, six-month follow-up data showed that pain scores in the steroid group had returned toward baseline, while the PRP group maintained statistically significant improvements in both pain and quality of life.
This is a single study, and its findings need to be replicated in larger trials before broad conclusions can be drawn. However, it suggests that the biological approach of PRP may offer a different recovery trajectory than the chemical suppression model of corticosteroids—a question that continues to be explored in ongoing research.
What Does the Clinical Research Show for Intradiscal PRP?
Some of the most frequently cited research on intradiscal PRP comes from clinical work by Tuakli-Wosornu and Lutz. In their studies, patients with symptomatic, degenerated discs who had not responded to conservative treatments showed statistically significant improvements that were maintained at two-year follow-up.
Below is a summary of reported two-year outcomes from these studies.
Reported Two-Year Outcomes for Intradiscal PRP
Reported Two-Year Outcomes for Intradiscal PRP
(Tuakli-Wosornu & Lutz clinical trial data)
- NRS Worst Pain
Reported Change: -2.12 points
Interpretation: Improvement* - Functional Rating Index (FRI)
Reported Change: -25.81 points
Interpretation: Improvement* - SF-36 Pain Domain
Reported Change: +23.99 points
Interpretation: Improvement* - SF-36 Physical Function
Reported Change: +18.04 points
Interpretation: Improvement*
These results are from specific study populations and may not be representative of all patients. Individual results vary.
From a practical standpoint, these procedures are typically performed in an outpatient setting in approximately 30 minutes, at a fraction of the cost of traditional spinal fusion. However, cost should not be the primary factor in a treatment decision, and patients should discuss all options—including the current evidence supporting each—with their physician.
Why Preparation Matters: The Mishra Classification
One of the challenges in evaluating PRP research is the significant variability in how PRP is prepared. Not all PRP formulations are the same.
The Mishra Classification system categorizes PRP based on:
- The presence of white blood cells (leukocyte-rich vs. leukocyte-poor)
- Whether the platelets have been exogenously activated prior to injection
Preparation methods—specifically “open” versus “closed” techniques—can result in vastly different platelet concentrations, ranging from a 2-fold to an 8.5-fold increase over baseline. Current research suggests that a 3- to 5-fold increase may be the most desirable range for clinical study.
This lack of standardization is one of the key reasons that outcomes can vary across different clinics and different studies, and it underscores the importance of choosing a provider who understands PRP preparation science.
Bone Marrow Concentrate (BMC): Preliminary Research for Cervical Disc Conditions
Research into regenerative approaches is not limited to the lower back. Bone Marrow Concentrate (BMC)—which contains a population of progenitor cells and platelets—is being investigated for complex cervical (neck) pathology.
A study by Pettine and Dordevic examined 182 patients who received BMC injections into one to five cervical discs. The participants had chronic neck pain, headaches, and radiating arm pain, often involving multiple disc levels.
The study reported:
- A 63% improvement in the Neck Disability Index (NDI), a measure of how neck pain affects daily life.
- A 67% improvement in pain scores (VAS).
- Consistent results regardless of how many levels were injected.
These findings are encouraging, but they come from a single study without a control group, and further research—including randomized controlled trials—is necessary before definitive clinical conclusions can be reached.
Patients considering BMC should discuss the current evidence base and their specific condition with their physician.
Looking Ahead: An Evolving Field
The landscape of spinal care is evolving. Alongside traditional surgical and pharmaceutical interventions, a growing number of researchers and clinicians are investigating whether regenerative approaches like PRP and BMC may offer meaningful benefits for patients with disc degeneration.
As the field matures—through better standardization of preparation protocols, larger randomized controlled trials, and a deeper understanding of cellular pathways like Keap1-Nrf2—we will gain a clearer picture of where these therapies fit in the continuum of care.
At Compass Pain and Wellness, we believe in providing our patients with accurate, up-to-date information about all available options so they can make informed decisions in partnership with their care team.
Important Disclosure
The information in this article is provided for educational purposes only and should not be interpreted as medical advice, a guarantee of outcomes, or a recommendation for any specific treatment.
PRP and Bone Marrow Concentrate (BMC) injections for spinal conditions are not FDA-approved therapies and are considered investigational by many medical organizations and insurance payers.
The clinical studies referenced are early-stage research; individual patient outcomes may vary significantly.
Always consult with a qualified healthcare provider to discuss the risks, benefits, and alternatives before making any treatment decisions.
Regulatory & Disclosure Statement
PRP and BMC for spinal conditions are not FDA-approved treatments. These procedures use autologous biological materials (derived from the patient’s own body) and are regulated under 21 CFR Part 1271. They are considered investigational by many medical organizations, and insurance coverage may not be available.
The research cited in this article represents early-stage clinical evidence from a limited number of studies. Results from clinical trials may not be representative of outcomes for all patients. Individual results depend on many factors, including the severity of degeneration, overall health, and the specific preparation protocol used.
Compass Pain and Wellness provides this information to help patients make informed decisions. We encourage all patients to discuss the full range of treatment options—including conservative care, interventional procedures, and surgical consultation—with their physician before pursuing any course of treatment.
References & Further Reading
- Ruiz-Lopez R, et al. Leukocyte-rich PRP vs. corticosteroids for caudal epidural injection in chronic degenerative spinal pain.
- Tuakli-Wosornu YA, Lutz GE, et al. Intradiscal platelet-rich plasma injection for chronic discogenic low back pain.
- Pettine K, Dordevic M. Cervical disc treatment with bone marrow concentrate.
- Systematic reviews on PRP for degenerative disc disease, including discussion of the Mishra Classification system.
- U.S. Food & Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). fda.gov
